Literature DB >> 2007534

Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.

O C Boerman1, C C van Niekerk, K Makkink, T G Hanselaar, P Kenemans, L G Poels.   

Abstract

The monoclonal antibodies OC 125, OV-TL 3, MOv 18, and OV-TL 23, which are directed against distinct ovarian carcinoma-associated antigens, are assessed in the present study for their diagnostic value. The expression of the antigens defined by these was studied in serial sections from 80 ovarian carcinomas and 103 nonovarian carcinomas obtained from 183 patients, using the immunoperoxidase technique. Immunoelectron microscopy demonstrated that the antigens were all localized on the tumor cell membrane. OC 125, OV-TL 3, and MOv 18 reacted positively with approximately 90% of the ovarian carcinoma samples (n = 80), whereas OV-TL 23 stained 76% of these samples. OC 125, OV-TL 3, and MOv 18 were also reactive with a majority of carcinomas derived from the cervix, endometrium and fallopian tube, while OV-TL 23 reactivity was primarily restricted to ovarian carcinomas. OC 125 and OV-TL 3 reacted respectively with 11% and 14% of the nongynecologic carcinomas tested (n = 64). Positive cases included breast, colon, and lung carcinomas. The antibodies MOv 18 and OV-TL 23 were found less reactive with nongynecologic carcinomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007534     DOI: 10.1097/00004347-199101000-00002

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  10 in total

1.  Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands.

Authors:  Wei He; Sumith A Kularatne; Kimberly R Kalli; Franklyn G Prendergast; Robert J Amato; George G Klee; Lynn C Hartmann; Philip S Low
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

2.  Synthesis, characterization, and in vitro assay of folic acid conjugates of 3'-azido-3'-deoxythymidine (AZT): toward targeted AZT based anticancer therapeutics.

Authors:  Anthony R Vortherms; Robert P Doyle; Dayuan Gao; Olivia Debrah; Patrick J Sinko
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-02       Impact factor: 1.381

3.  Anticancer conjugates and cocktails based on methotrexate and nucleoside synergism.

Authors:  Anthony R Vortherms; Hester N Dang; Robert P Doyle
Journal:  Clin Med Oncol       Date:  2009-03-20

4.  Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.

Authors:  P Garin-Chesa; I Campbell; P E Saigo; J L Lewis; L J Old; W J Rettig
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

5.  Changes in expression of differentiation markers between normal ovarian cells and derived tumors.

Authors:  C C Van Niekerk; F C Ramaekers; A G Hanselaar; J Aldeweireldt; L G Poels
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

6.  Immunohistochemical profile of ovarian inclusion cysts in patients with and without ovarian carcinoma.

Authors:  K R Mittal; S Goswami; R I Demopoulos
Journal:  Histochem J       Date:  1995-02

7.  In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry.

Authors:  Wei He; Haifeng Wang; Lynn C Hartmann; Ji-Xin Cheng; Philip S Low
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-29       Impact factor: 11.205

8.  Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Authors:  Wolfgang Ebel; Eric L Routhier; Brian Foley; Sara Jacob; Jennifer M McDonough; Rina K Patel; Howard A Turchin; Qimin Chao; J Bradford Kline; Lloyd J Old; Martin D Phillips; Nicholas C Nicolaides; Philip M Sass; Luigi Grasso
Journal:  Cancer Immun       Date:  2007-03-09

9.  Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.

Authors:  Daniel J O'Shannessy; Elizabeth B Somers; Leslie M Palmer; Robert P Thiel; Pankaj Oberoi; Ryan Heath; Lisa Marcucci
Journal:  J Ovarian Res       Date:  2013-04-17       Impact factor: 4.234

10.  Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding.

Authors:  F P Lindberg; H D Gresham; E Schwarz; E J Brown
Journal:  J Cell Biol       Date:  1993-10       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.